- Home
- LCNB vs TRVI Comparison
LCNB vs TRVI Comparison
Compare LCNB & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCNB
- TRVI
- Stock Information
- Founded
- LCNB 1877
- TRVI 2011
- Country
- LCNB United States
- TRVI United States
- Employees
- LCNB N/A
- TRVI N/A
- Industry
- LCNB Major Banks
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- LCNB Finance
- TRVI Health Care
- Exchange
- LCNB Nasdaq
- TRVI Nasdaq
- Market Cap
- LCNB 212.3M
- TRVI 211.4M
- IPO Year
- LCNB N/A
- TRVI 2019
- Fundamental
- Price
- LCNB $15.83
- TRVI $4.05
- Analyst Decision
- LCNB
- TRVI Strong Buy
- Analyst Count
- LCNB 0
- TRVI 8
- Target Price
- LCNB N/A
- TRVI $9.31
- AVG Volume (30 Days)
- LCNB 26.1K
- TRVI 4.2M
- Earning Date
- LCNB 01-29-2025
- TRVI 11-06-2024
- Dividend Yield
- LCNB 5.77%
- TRVI N/A
- EPS Growth
- LCNB N/A
- TRVI N/A
- EPS
- LCNB 0.52
- TRVI N/A
- Revenue
- LCNB $74,686,000.00
- TRVI N/A
- Revenue This Year
- LCNB N/A
- TRVI N/A
- Revenue Next Year
- LCNB $15.49
- TRVI N/A
- P/E Ratio
- LCNB $29.28
- TRVI N/A
- Revenue Growth
- LCNB 3.03
- TRVI N/A
- 52 Week Low
- LCNB $12.42
- TRVI $1.27
- 52 Week High
- LCNB $17.92
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- LCNB 36.98
- TRVI 64.87
- Support Level
- LCNB $15.51
- TRVI $4.08
- Resistance Level
- LCNB $16.84
- TRVI $4.68
- Average True Range (ATR)
- LCNB 0.55
- TRVI 0.38
- MACD
- LCNB -0.21
- TRVI 0.15
- Stochastic Oscillator
- LCNB 22.75
- TRVI 73.00
About LCNB LCNB Corporation
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.